268 related articles for article (PubMed ID: 19204649)
1. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
4. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
5. Lamotrigine and aseptic meningitis.
Simms KM; Kortepeter C; Avigan M
Neurology; 2012 Mar; 78(12):921-7. PubMed ID: 22357718
[TBL] [Abstract][Full Text] [Related]
6. Relationship of atypical antipsychotics with development of diabetes mellitus.
Citrome LL; Jaffe AB
Ann Pharmacother; 2003 Dec; 37(12):1849-57. PubMed ID: 14632602
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Kimura G; Kadoyama K; Brown JB; Nakamura T; Miki I; Nisiguchi K; Sakaeda T; Okuno Y
Int J Med Sci; 2015; 12(2):135-40. PubMed ID: 25589889
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
[TBL] [Abstract][Full Text] [Related]
9. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
Martin D; Menschik D; Bryant-Genevier M; Ball R
Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
[TBL] [Abstract][Full Text] [Related]
10. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy.
Gianfrancesco F; Wang RH; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(1):9-17. PubMed ID: 16517448
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
Gianfrancesco F; White R; Wang RH; Nasrallah HA
J Clin Psychopharmacol; 2003 Aug; 23(4):328-35. PubMed ID: 12920407
[TBL] [Abstract][Full Text] [Related]
12. Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics.
Hauben M
Pharmacotherapy; 2004 Sep; 24(9):1122-9. PubMed ID: 15460172
[TBL] [Abstract][Full Text] [Related]
13. Glucose intolerance with atypical antipsychotics.
Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
[TBL] [Abstract][Full Text] [Related]
14. Serious adverse events with infliximab: analysis of spontaneously reported adverse events.
Hansen RA; Gartlehner G; Powell GE; Sandler RS
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):729-35. PubMed ID: 17481964
[TBL] [Abstract][Full Text] [Related]
15. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics.
Citrome L; Collins JM; Nordstrom BL; Rosen EJ; Baker R; Nadkarni A; Kalsekar I
J Clin Psychiatry; 2013 Dec; 74(12):1199-206. PubMed ID: 24434088
[TBL] [Abstract][Full Text] [Related]
17. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
[TBL] [Abstract][Full Text] [Related]
18. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
19. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
